Translational studies of a20 in atherosclerosis and cardiovascular disease

Advances in Experimental Medicine and Biology

Volumn 809, Issue , 2014, Pages 83-101

  McGillicuddy, Fiona C ^a,d   Moll, Herwig P ^b   Farouk, Samira ^a   Damrauer, Scott M ^b,c   Ferran, Christiane ^b   Reilly, Muredach P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; SYNAPSIN II; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; DNA BINDING PROTEIN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

A20 GENE; ANTIAPOPTOTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ATHEROGENESIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROTECTION; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; ENVIRONMENTAL FACTOR; GENE FUNCTION; GENE TARGETING; GENETIC RISK; HEART FAILURE; HEART PROTECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; VASCULAR ENDOTHELIAL CELL; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; ARTICLE; ATHEROSCLEROSIS; FEMALE; MALE; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CYTOPROTECTION; DNA-BINDING PROTEINS; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; NF-KAPPA B; NUCLEAR PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908046980     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0398-6_6     Document Type: Chapter

References (96)

1. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338:b2376; PMID: 19567909; http://dx.doi.org/lO.I136/bmj.b2376.
2. Go AS, Mozaffarian D, Roger VL, Benjamin El, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--20 13 update: a report from the American Heart Association. Circulation 2013; 127: 143-52; PMID:23283859; http://dx.doi.org/10.11611CIR.ObO I 3e318282ab8f.
3. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
4. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
5. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6:508-19; PMID: 16778830; http://dx.doi.org/l0.1038/nriI882.
6. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
7. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
8. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
9. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, Fijneman RJ, et al. Inhibition ofNF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. 1 Clin Invest 2003; 112: 1176-85; PMID: 14561702.
10. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
11. Schreyer SA, Peschon 11, LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Bioi Chern 1996; 271:26174-8; PMID:8824264; http://dx.doi.org/lO.l074/jbc.271.42.26174.
12. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson 1, 10vinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Bioi 2004; 24:2137-42; PMID: 15345516; http://dx.doi.org/l0.1161/01.ATV.0000143933.20616.1 b.
13. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
14. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
15. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
16. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
17. Patel VI, Daniel S, Longo CR, Shrikhande GV, Scali ST, Czismadia E, et al. A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia. FASEB J 2006; 20: 1418-30; PMID: 16816117; http://dx.doi.org/lO.l096/fj.05-4981com.
18. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
19. Siracuse JJ, Fisher MD, da Silva CG, Peterson CR, Csizmadia E, Moll HP, etal. A20-mediated modulation ofint1ammatory and immune responses in aortic allografts and development of transplant arteriosclerosis. Transplantation 2012; 93:373-82; PMTD:22245872; http://dx.doi.orgI10.1097/TP.ObOI3e3182419829.
20. Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH, et al. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 2007; 115:1885-94; PMID:17389268; http://dx.doi.org/10.11611 CTRCULA TTONAHA.l 06.656835.
21. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
22. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18:2195-224; PMTD:15371334; http://dx.doi.orgIl0.110Ilgad.1228704.
23. Grobbee DE, Bots M. Atherosclerotic disease regression with statins: studies using vascular markers. Int 1 Cardiol2004; 96:447-59; PMID:15301899; http://dx.doi.org/lO.1016/j.ijcard.2004.01.005.
24. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
25. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
26. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
27. Monaco C, Paleo log E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 2004; 61:671-82; PMTD: 14985064; http://dx.doi.orgI10.1 016/j. cardiores.2003.11.038.
28. Brand K, Page S, RogIer G, Bartsch A, Brandl R, Knuechel R, et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-22; PMID:8601637; http://dx.doi.org/l 0.1 I 72/JCIl 18598.
29. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
30. Ghosh S, Hayden MS. Celebrating 25 years of NF-KB research. ImmUllol Rev 2012; 246:5-13; PMTD:22435544; http://dx.doi.org/l0.llll/j.1600-065X.2012.01111.x.
31. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
32. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
33. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Twakura Y, et al. Lack of inter leu kin-l beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Bioi 2003; 23:656-60; PMTD:12615675; http://dx.doi.org/10.1161/01.ATV.0000064374.15232.C3.
34. Chi H, Messas E, Levine RA, Graves DT, AmarS. Interleukin-l receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation 2004; 110: 1678-85; PMID: 15353494; http://dx.doi.org/l0.116110I.CIR.0000 142085.39015.31.
35. Wolfrum S, Teupser D, Tan M, Chen KY, Breslow JL. The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression ofNF-kappaB target genes. Proc NatlAcad Sci U SA20D7; 104: 18601-6; PMID: 18006655;http://dx.doi.org/10.1073/pnas.0709DIII04.
36. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
37. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, et a!. Interleukin-I 0 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 2003; 9:10-7; PMID:12765335.
38. MaliatZ, Besnard S, DuriezM, Deleuze V, EmmanuelF, BureauMF, eta!. Protective role ofinterleukin-I 0 in atherosclerosis. CircRes 1999; 85:eI7-24; PMID:I0521249;http://dx.doi.org/IO.l16110I.RES.85.8.eI7.
39. Von Der Thtisen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ, Biessen EA. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer ofinterleukin-IO in LDLr-/­ mice. FASEB J 2001; 15:2730-2; PMID: 11687507.
40. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
41. Daniel S, Arvelo MB, Patel VI, Longo CR, Shrikhande G, Shukri T, et a!. A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation. Blood 2004; 104:2376-84; PMID:15251990; http://dx.doi.orgI10.1182/blood-2003-02-0635.
42. Heyninck K, Beyaert R. A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions. Trends Biochem Sci 2005; 30:1-4; PMID:15653317; http://dx.doi.orgI10.1016/j.tibs.2004.11.001.
43. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
44. Kunter U, Floege J, von Jiirgensonn AS, Stojanovic T, Merkel S, Grone HJ, et a!. Expression of A20 in the vessel wall of rat-kidney allografts correlates with protection from transplant arteriosclerosis. Transplantation 2003; 75:3-9; PMTD:12544863; http://dx.doi.orgI10.1097/00007890-200301150-00002.
45. Li HL, Wang AB, Zhang R, Wei YS, Chen HZ, She ZG, et a!. A20 inhibits oxidized low-density lipoprotein-induced apoptosis through negative FaslFas ligand-dependent activation of caspase-8 and mitochondrial pathways in murine RA W264.7 macrophages. J Cell Physiol 2006; 208:307-18; PMTD: 16646083; http://dx.doi.orgI10.1002/jcp.20665.
46. Sun L, Chen ZJ. The novel functions of ubi quit in at ion in signaling. Curr Opin Cell Bioi 2004; 16: 119-26; PMTD: 15196553; http://dx.doi.org/I 0.1 0 16/j.ceb.2004.02.005.
47. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5: 1052-60; PMID: 15334086; http://dx.doi.org/10.1038/niIII0.
48. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
49. Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, Ferran C. A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. J Bioi Chern 1996; 271:18068-73; PMTD:8663499; http://dx.doi.orgI10.1074/jbc.271.30.18068.
50. Longo CR, Arvelo MB, Patel VI, Daniel S, Mahiou J, Grey ST, et al. A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Circulation2003; 108: 1113-8; PMID: 12885753; http://dx.doi.org/10.1161/01.CIR.0000083718.76889.DO.
51. Turer EE, Tavares RM, Mortier E, Advincula R, Lee B, Homeostatic MyD88-dependent signals cause lethal intlamMation in the absence of A20. JExp Med 2008; 205:451-64; PMID: 18268035; http://dx.doi.org/l 0.1 084/jem.200711 08.
52. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
53. Silverman N, Fitzgerald K. DUBbing down innate immunity. Nat Immunol 2004; 5:1010-2; PMID: 15454928; http://dx.doi.org/l0.1038/niI004-1 0 10.
54. Pearson JD. Normal endothelial cell function. Lupus 2000; 9:183-8; PMTD:I0805485; http://dx.doi. org/l0.11911096120300678828299.
55. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
56. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988; 58:249-61; PMID:3279259.
57. Scott-Burden T, Vanhoutte PM. Regulation of smooth muscle cell growth by endothelium-derived factors. Tex Heart Inst J 1994; 21:91-7; PMID:8180516.
58. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
59. Longo CR, Patel VI, Shrikhande GV, Scali ST, Csizmadia E, Daniel S, et al. A20 protects mice from lethal radical hepatectomy by promoting hepatocyte proliferation via a p21 wafl-dependent mechanism. Hepatology 2005; 42:156-64; PMID:15962316; http://dx.doi.orgI10.1002/hep.20741.
60. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
61. Ruberg FL, Leopold JA, Loscalzo J. Atherothrombosis: plaque instability and thrombogenesis. Prog Cardiovasc Dis 2002; 44:381-94; PMID: 12024336; http://dx.doi.orgI10.1053/pcad.2002.123469.
62. Cirino G, Fiorucci S, Sessa WC. Endothelial nitric oxide synthase: the Cinderella of inflammation? Trends Pharmacol Sci 2003; 24:91-5; PMID: 12559774; http://dx.doi.orgI10.1016/S0165-6147(02)00049-4.
63. Connelly L, Palacios-Callender M, Ameixa C, Moncada S, Hobbs AJ. Biphasic regulation ofNF-K B activity underlies the pro-and anti-inflammatory actions of nitric oxide. JImmunol2001; 166:3873-81; PMID: 11238631.
64. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
65. Iwashina M, Shichiri M, Marumo F, Hirata Y. Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells. Circulation 1998; 98: 1212-8; PMID:9743513; http://dx.doi. orgll 0.1161/0 I.CIR.98.12.1212.
66. Wang GR, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME. Mechanism of platelet inhibition bynitric oxide: in vivo phosphorylation ofthromboxane receptor by cyclic GMP-dependent protein kinase. Proc Nat! Acad Sci USA 1998; 95:4888-93; PMID:9560198; http://dx.doi.orgIl0.1073/pnas.95.9.4888.
67. Liu JW, Dunoyer-Geindre S, Blot-Chabaud M, Sabatier F, Fish RJ, Bounameaux H, et al. Generation of human inflammation-resistant endothelial progenitor cells by A20 gene transfer. J Vasc Res 2010; 47: 157-67; PMID: 19851077; http://dx.doi.org/10.1159/000250094.
68. Rekhter MD, Gordon D. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am J Pathol 1995; 147:668-77; PMID:7677178.
69. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
70. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
71. Pollman MJ, Hall JL, Mann MJ, Zhang L, Gibbons GH. Inhibition ofneointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 1998; 4:222-7; PMID:9461197; http://dx.doi.orgl I 0.1 03 8/nm02 98-222.
72. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
73. Wang AB, Li HL, Zhang R, She ZG, Chen HZ, Huang Y, et al. A20 attenuates vascular smooth muscle cell proliferation and migration through blocking PT3kl Akt singling in vitro and in vivo. J Biomed Sci 2007; 14:357-71; PMID: 17260 188; http://dx.doi.org/10.1007/s11373-007-9150-x.
74. Tullius SG, Tilney NL. Both alloantigen-dependent and-independent factors influence chronic allograft rejection. Transplantation 1995; 59:313-8; PMID:7871557.
75. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
76. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218; PMID: 17353295; http://dx.doi.orgI10.1210/10.1210/er.2006-0038.
77. Boonyasrisawat W, Eberle D, Bacci S, Zhang YY, Nolan D, Gervino EV, et al. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes 2007; 56:499-505; PMID:I7259397; http://dx.doi.org/IO.2337/db06-0946.
78. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
79. Damrauer SM, Studer P, da Silva CG, Longo CR, Ramsey HE, Csizmadia E, et al. A20 modulates lipid metabolism and energy production to promote liver regeneration. PLoS One 2011; 6:el7715; PMlD:21437236; http://dx.doi.orgIl0.1371/journal.pone.0017715.
80. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
81. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
82. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P, Wilensky R, et al. CXCLl6 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coli Cardiol 2007; 49:442-9; PMlD: 17258089; http://dx.doi.org/IO.1 016/j.jacc.2006.09.034.
83. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
84. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
85. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
86. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-25; PMTD:15919781; http://dx.doi.orgIl0.2337/diabetes.54.6.1615.
87. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
88. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
89. Shaw J, Eydelnant lA, Kirshenbaum LA. Transgenic expression of A20 prevents cardiac cell death and myocardial dysfunction after myocardial infarction. Circulation 2007; 115:1827-9; PMlD:17420361; http://dx.doi.org/10.1161/CIRCULA TTONAHA.l 06.687475.
90. Huang H, Tang QZ, Wang AB, Chen M, Yan L, Liu C, et al. Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase I-dependent signaling. Hypertension 2010; 56:232-9; PMlD:20585109; http://dx.doi.orgIl0.1161/ HYPERTENSIONAHA.11O.149963.
91. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
92. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
93. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
94. Perkins ND.lntegrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell BioI 2007; 8:49-62; PMTD: 17183360; http://dx.doi.orgI10.1038/nrm2083.
95. Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 2011; 43:339-44; PMlD:21378988; http://dx.doi.org/10.1038/ng.782.
96. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, eta!.; Cardiogenics; CARDIoGRAM Consortium. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011; 43:333-8; PMTD:21378990; http://dx.doi.org/10.1038/ng.784.